Last $800.00 MXN
Change Today +11.00 / 1.39%
Volume 419.0
MRK* On Other Exchanges
Symbol
Exchange
New York
Mexico
EN Paris
Sao Paulo
Frankfurt
As of 4:09 PM 09/23/14 All times are local (Market data is delayed by at least 15 minutes).

Transactions by MERCK & CO. INC. (MRK*) in the last 6 months

Announced 06/9/14
3.85B for Idenix Pharmaceuticals Inc.
Merger/Acquisition

Merck & Co. Inc. (NYSE:MRK) entered into a definitive agreement to acquire Idenix Pharmaceuticals Inc. (NasdaqGS:IDIX) from T. Rowe Price Associates, Inc., Nomura International plc, Brookside Capital Management, LLC, The Baupost Group, LLC and other shareholders for $3.84 billion in cash on June 8, 2014. Under the terms of the agreement, Merck will pay $24.5 per share. Under the terms of the agreement, Merck, through a subsidiary, will initiate a tender offer to acquire ...
Read More


MRK*'s price was unchanged after the transaction was announced on 06/9/14.
Investor / Buyer
Merck & Co. Inc.
Creditor / Lender
Brookside Capital Management, LLC
MPM BioVentures I, L.P.
MPM Capital
Nomura International plc
Novartis Pharma AG
Novartis Venture Funds
T. Rowe Price Associates, Inc.
The Baupost Group, LLC
Financial Advisor
Centerview Partners LLC
Legal Advisor
Sullivan & Cromwell LLP
 
Announced 05/13/14
600.00M for Merck & Co. Inc., Assets in Ophthalmology in Japan and key Markets in Europe and Asia Pacific
Merger/Acquisition

Santen Pharmaceutical Co. Ltd. (TSE:4536) entered into an agreement to acquire ophthalmology assets in Japan and key markets in Europe and Asia Pacific from Merck & Co. Inc. (NYSE:MRK) for $600 million on May 13, 2014. Under the terms, Santen Pharmaceutical Co. Ltd. will make an upfront payment of approximately $600 million and additional payments based on defined sales milestones. Santen intends to fund the acquisition with a combination of cash on hand and bank loans. ...
Read More


MRK*'s price was unchanged after the transaction was announced on 05/13/14.
Investor / Buyer
Santen Pharmaceutical Co. Ltd.
Creditor / Lender
Merck & Co. Inc.
 
Announced 05/13/14
Merck & Co. Inc., Microbial Process Development and Manufacturing Operations in Boulder, Colorado
Merger/Acquisition

KBI Biopharma Inc. acquired microbial process development and manufacturing operations in Boulder, Colorodo from Merck & Co. Inc. (NYSE:MRK) on May 13, 2014. Under the agreement, KBI will provide ongoing development and manufacturing services to Merck & Co. Inc. as well as to third-party customers. All 30 Merck employees in Boulder have been retained by KBI. Fintan Walton of PharmaVentures Ltd. acted as financial advisor to Merck & Co.


MRK*'s price was unchanged after the transaction was announced on 05/13/14.
Investor / Buyer
KBI Biopharma Inc.
Creditor / Lender
Merck & Co. Inc.
 
Announced 05/6/14
14.20B for Merck & Co., Inc., Merck Consumer Care Business
Merger/Acquisition

Bayer AG (DB:BAYN) signed an agreement to acquire the consumer care business of Merck & Co., Inc. (NYSE:MRK) for $14.2 billion in cash on May 5, 2014. The consideration is inclusive of assumption of liabilities and payment of debt at closing. Bayer will acquire the business as part of an auction. Under the terms of the agreement, Bayer AG will acquire Merck’s existing OTC business, including the global trademark and prescription rights for Claritin and Afrin. Concurrent ...
Read More


MRK*'s price was unchanged after the transaction was announced on 05/6/14.
Investor / Buyer
Bayer AG
Creditor / Lender
Merck & Co. Inc.
 
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MRK*:MM $800.00 MXN +11.00

MRK* Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bayer AG €111.01 EUR -1.82
GlaxoSmithKline PLC 1,422 GBp -21.50
Pfizer Inc $30.05 USD -0.13
Roche Holding AG SFr.282.20 CHF -1.00
Sanofi €87.41 EUR -1.46
View Industry Companies
 

Industry Analysis

MRK*

Industry Average

Valuation MRK* Industry Range
Price/Earnings 31.9x
Price/Sales 4.1x
Price/Book 3.6x
Price/Cash Flow 31.1x
TEV/Sales 3.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MERCK & CO. INC., please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.